Article Sidebar

PDF (Tiếng Việt)
Published: 2023-09-20
Abstract Views: 217
Views PDF (Tiếng Việt): 159
DOI: https://doi.org/10.52852/tcncyh.v169i8.1860
Issue
Vol. 169 No. 8 (2023)
Section
Các bài báo
How to Cite
Hậu, T. T., & Thế, Đào M. (2023). 29. The clinical, subclinical, and the efficacy of first-line chemotherapy in stage IV non-small cell lung cancer patients harboring EGFREGFR exon 20 insertions. Journal of Medical Research, 169(8), 242-250. https://doi.org/10.52852/tcncyh.v169i8.1860

29. The clinical, subclinical, and the efficacy of first-line chemotherapy in stage IV non-small cell lung cancer patients harboring EGFREGFR exon 20 insertions

Tran Thi Hau, Dao Minh The

Main Article Content

Abstract

Epidermal growth factor receptor mutation exon 20 insertion ranks third in all non-small cell lung cancer harboring EGFR mutation. The disease has a poor prognosis and is often resistant to tyrosine kinase inhibitors drugs, so the standard treatment is still platinum-based chemotherapy. This is a cross-sectional descriptive study of 31 patients with stage IV non-small cell lung cancer harboring EGFR exon 20 insertions treated with first-line platinum-based chemotherapy from January 2019 to June 2023 at K Hospital; we report clinical and subclinical features and the efficacy of first-line chemotherapy for the aforementioned patients. The study showed the mean age was 59.14, predominantly males; the male/female ratio was 2.1/1. Most patients were former smokers (67.7%) and their performance status (PS) 1 was 77.4%. Prolonged cough was the most common reason for hospitalization, followed by chest pain. Hemoptysis was the lowest rate. T4 was the highest rate at 48.4%. Lymph nodes metastatic N2-3 was 71%. Bone was the most propensity site for metastatic, followed by contralateral lung, pleural, brain, and adrenal gland metastasis. Adenocarcinoma was the predominant histology at 93.5%. Pemetrexed-carboplatin was the most commonly used, accounting for 51.6%, and the overall response to chemotherapy was 25.8%. Median progression-free survival was five months. The study revealed that stage IV non-small cell lung cancer patients harboring EGFR exon 20 insertions was commonly seen in young males with bone metastasis; the disease has a poor prognosis with the overall response rate and progression-free survival were relatively low. 

Article Details

Keywords

Non-small cell lung cancer, EGFR, exon 20 insertion

References

1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5(9): 2892-2911.
2. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018; 13(10): 1560-1568. doi:10.1016/j.jtho.2018.06.019.
3. Hou J, Li H, Ma S, et al. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomarker Research. 2022; 10(1): 21. doi:10.1186/s40364-022-00372-6.
4. Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014; 25(1): 126-131. doi:10.1093/annonc/mdt418.
5. Zwierenga F, van Veggel B, Hendriks LEL, et al. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial. Lung Cancer. 2022; 170:133-140. doi:10.1016/j.lungcan.2022.06.012.
6. Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020; 145: 186-194. doi:10.1016/j.lungcan.2020.03.014.
7. Morita C, Yoshida T, Shirasawa M, et al. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep. 2021; 11: 18762. doi:10.1038/s41598-021-98275-3.
8. Arcila ME, Nafa K, Chaft JE, et al. EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Mol Cancer Ther. 2013; 12(2): 220-229. doi:10.1158/1535-7163.MCT-12-0620.
9. Sompallae RR, Dundar B, Guseva NV, Bossler AD, Ma D. EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features. Frontiers in Oncology. 2023; 13. Accessed August 17, 2023. https://www.frontiersin.org/articles/10.3389/fonc.2023.1163485.
10. Yang S, Wang Y, Zhao C, et al. Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations. Transl Lung Cancer Res. 2021; 10(2): 753-765. doi:10.21037/tlcr-20-559.
11. Lin HM, Yin Y, Crossland V, Wu Y, Ou SHI. EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States. JTO Clin Res Rep. 2022; 3(3): 100285. doi:10.1016/j.jtocrr.2022.100285.
12. Ou SHI, Hong JL, Christopoulos P, et al. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC. Journal of Thoracic Oncology. 2023; 18(6): 744-754. doi:10.1016/j.jtho.2023.01.086.
13. Xu CW, Wang WX, Wang D, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res. 2020; 9(5): 1853-1861. doi:10.21037/tlcr-20-382.